Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only the dosing-frequency aspect (once daily) is partially supported by the provided label excerpts; multiple pharmacokinetic and hepatic-impaired exposure/duration claims are unsupported by the available label text.
Category Scores
Accurate Statements
Tolvaptan is typically dosed once daily in approved uses.
2.1 Recommended Dosage: "15 mg administered once daily"; "Increase the dose ... to 30 mg once daily"; "maximum of 60 mg once daily".
Unsupported Statements
Tolvaptan has a terminal plasma half-life of about 8 hours in adults.
No FDA-approved label language provided in the available excerpts states an ~8-hour terminal plasma half-life.
Tolvaptan half-life/clearance is influenced by overall drug exposure and patient factors.
No corresponding label statement provided in the available excerpts.
In hepatic impairment, tolvaptan exposure may be increased.
No label statement provided in the available excerpts addressing hepatic impairment exposure.
In hepatic impairment and other settings where drug handling may differ, tolvaptan levels may fall differently, affecting the effective duration.
No label statement provided in the available excerpts supporting differential level decline/effective duration across hepatic impairment or other settings.
Because of an approximately 8-hour half-life, tolvaptan levels drop substantially after dosing.
The premise (~8-hour half-life) and the derived mechanistic conclusion are not supported by the available label excerpts.
The overall effect of tolvaptan depends on urine response and treatment goals, not only half-life.
No label statement provided in the available excerpts framing treatment effect as depending on urine response/treatment goals independent of half-life.
Contradictions
Important Omissions
The evaluation did not assess key label-mandated safety/administration requirements relevant to initiation (e.g., hospital initiation/re-initiation and frequent monitoring of serum electrolytes/volume) because the claim set focused on pharmacokinetics rather than these label instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported PK/half-life and hepatic-impairment exposure/duration claims could misinform dosing expectations, but no label-contradicting dosing instructions were provided. Only the once-daily frequency claim is supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major pharmacokinetic/half-life and hepatic impairment exposure/duration claims are unsupported by the supplied label excerpts.
Suggested Improvement
Limit statements to label-supported dosing instructions (once-daily and titration/max dose) and remove or cite specific FDA label text for half-life and hepatic impairment exposure/clearance relationships.